Skip to Content

Maxipime

Pronunciation

Generic Name: cefepime hydrochloride
Dosage Form: injection, powder, for solution

Indications and Usage for Maxipime

Pneumonia

Maxipime is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.

Empiric Therapy for Febrile Neutropenic Patients

Maxipime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1)].

Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis)

Maxipime is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria.

Uncomplicated Skin and Skin Structure Infections

Maxipime is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

Complicated Intra-abdominal Infections (used in combination with metronidazole)

Maxipime is indicated in the treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14.2)].

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Maxipime and other antibacterial drugs, Maxipime should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Maxipime Dosage and Administration

Dosage for Adults

The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer Maxipime intravenously over approximately 30 minutes.

Table 1: Recommended Dosage Schedule for Maxipime in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min
*or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently.
**Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli.
§For P. aeruginosa, use 2 g IV every 8 hours.

Site and Type of Infection

Dose

Frequency

Duration

(days)

     

Adults

Intravenous (IV)/Intramuscular (IM)

Moderate to Severe Pneumonia§

1 to 2 g IV

Every 8 to
12 hours

10

Empiric therapy for febrile neutropenic patients

2 g IV

Every 8 hours

7*

Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis

0.5 to 1 g

IV/IM**

Every 12 hours

7 to 10

Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis

2 g IV

Every 12 hours

10

Moderate to Severe Uncomplicated Skin and Skin Structure Infections

2 g IV

Every 12 hours

10

Complicated Intra-abdominal Infections§ (used in combination with metronidazole)

2 g IV

Every 8 to
12 hours

7 to 10

Pediatric Patients (2 months up to 16 years)

The maximum dose for pediatric patients should not exceed the recommended adult dose.

The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is:

50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).
For moderate to severe pneumonia due to P. aeruginosa give 50 mg per kg per dose, every
8 hours.
50 mg per kg per dose, every 8 hours for febrile neutropenic patients.

Dosage Adjustments in Patients with Renal Impairment

Adult Patients

Adjust the dose of Maxipime in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of Maxipime should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis. The recommended doses of Maxipime in patients with renal impairment are presented in Table 2.

When only serum creatinine is available, the following formula (Cockcroft and Gault equation)4 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:

Males: Creatinine Clearance (mL/min) =

       Weight (kg) x (140 – age)         

72 × serum creatinine (mg/dL)

 

Females: 0.85 × above value

Table 2: Recommended Dosing Schedule for Maxipime in Adult Patients With Creatinine Clearance Less Than or Equal to 60 mL/min
*
On hemodialysis days, cefepime should be administered following hemodialysis. Whenever possible, cefepime should be administered at the same time each day.

Creatinine
Clearance (mL/min)

Recommended Maintenance Schedule

Greater than 60

500 mg every
12 hours

1 g every
12 hours

2 g every
12 hours

2 g every

8 hours

30 to 60

500 mg

every 24 hours

1 g

every 24 hours

2 g

every 24 hours

2 g

every 12 hours

11 to 29

500 mg

every 24 hours

500 mg

every 24 hours

1 g

every 24 hours

2 g

every 24 hours

Less than 11

250 mg

every 24 hours

250 mg

every 24 hours

500 mg

every 24 hours

1 g

every 24 hours

Continuous Ambulatory Peritoneal Dialysis (CAPD)

500 mg

every 48 hours

1 g

every 48 hours

2 g

every 48 hours

2 g

every 48 hours

 

Hemodialysis*

1 g on day 1, then 500 mg every 24 hours thereafter

1 g

every 24 hours

In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), Maxipime may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).

In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of Maxipime for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.

Maxipime should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2).

Pediatric Patients

Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3)], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.

Preparation of Maxipime for Intravenous Infusion

Vials

Constitute the 0.5 gram, 1 gram, or 2 grams vial, of Maxipime with the one of the following diluents:
o
Sterile Water for Injection
o
0.9% Sodium Chloride Injection
o
5% Dextrose Injection
o
0.5% or 1% Lidocaine Hydrochloride Injection
o
Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol
Dilute reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial):
o
0.9% Sodium Chloride Injection
o
5% and 10% Dextrose Injection
o
M/6 Sodium Lactate Injection
o
5% Dextrose and 0.9% sodium Chloride Injection
o
Lactated Rings and 5% Dextrose Injection
o
Normosol™-R and Normosol™-M in 5% Dextrose Injection
Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.
Administer the resulting intravenous infusion over approximately 30 minutes.
Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.

ADD-Vantage Vials

Constitute only with 50 mL or 100 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection in ADD-Vantage flexible diluent containers as described in the instructions for reconstitution [see Dosage and Administration (2.7)].

Preparation for Intramuscular Administration

Constitute Maxipime vials 0.5 gram, 1 gram and 2 grams with one of the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride, 5% Dextrose Injection, 0.5% or 1% Lidocaine Hydrochloride, or Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol. Refer to Table 3 below for the amount of diluent to be added to each vial.

Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.

Table 3: Preparation of Constituted Solutions of Maxipime for Injection

Single-Dose Vials for Intravenous (IV)/Intramuscular (IM)Administration

Amount of Diluent

to be added
(mL)

Approximate Available Volume (mL)

Approximate Cefepime Concentration

(mg/mL)

Cefepime vial content

500 mg (IV)

5

5.6

100

500 mg (IM)

1.3

1.8

280

1 g (IV)

10

11.3

100

1 g (IM)

2.4

3.6

280

2 g (IV)

10

12.5

160

ADD-Vantage

1 g vial

1 g vial

2 g vial

2 g vial


50

100

50

100


50

100

50

100


20

10

40

20

Compatibility and Stability

Intravenous Maxipime

Intravenous Infusion Compatibility

Maxipime vials are compatible at concentrations between 1 mg per mL and 40 mg per mL with the following intravenous infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection, Normosol™-R, and Normosol™-M in 5% Dextrose Injection. These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F).

Maxipime in ADD-Vantage vials are stable at concentrations of 10 to 40 mg per mL in 5% Dextrose Injection or 0.9% Sodium Chloride Injection for 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F).

Admixture Compatibility

Maxipime admixture compatibility information is summarized in Table 4.

Table 4: Cefepime Admixture Stability
NS = 0.9% Sodium Chloride Injection.
D5W = 5% Dextrose Injection.
na = not applicable.
RT/L = Ambient room temperature and light.

Stability Time for

Maxipime
Concentration

Admixture and
Concentration

Intravenous (IV) Infusion

Solutions

RT/L
(20° to 25°C)

Refrigeration
(2° to 8°C)

40 mg/mL

Amikacin

6 mg/mL

NS or D5W

24 hours

7 days

40 mg/mL

Ampicillin

1 mg/mL

D5W

8 hours

8 hours

40 mg/mL

Ampicillin

10 mg/mL

D5W

2 hours

8 hours

40 mg/mL

Ampicillin

1 mg/mL

NS

24 hours

48 hours

40 mg/mL

Ampicillin

10 mg/mL

NS

8 hours

48 hours

4 mg/mL

Ampicillin

40 mg/mL

NS

8 hours

8 hours

4 to 40 mg/mL

Clindamycin

Phosphate

0.25 to 6 mg/mL

NS or D5W

24 hours

7 days

4 mg/mL

Heparin

10 to 50 units/mL

NS or D5W

24 hours

7 days

4 mg/mL

Potassium Chloride

10 to 40 mEq/L

NS or D5W

24 hours

7 days

4 mg/mL

Theophylline

0.8 mg/mL

D5W

24 hours

7 days

1 to 4 mg/mL

na

Aminosyn™ II

4.25% with

electrolytes and calcium

8 hours

3 days

0.125 to

0.25 mg/mL

na

Inpersol™

with 4.25% dextrose

24 hours

7 days

Maxipime Admixture Incompatibility

Do not add solutions of Maxipime, to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction. However, if concurrent therapy with Maxipime is indicated, each of these antibiotics can be administered separately.

Intramuscular Maxipime

Maxipime constituted as directed is stable for 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or for 7 days in a refrigerator 2°C to 8°C (36°F to 46°F) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride.

Intramuscular and Intravenous Maxipime

As with other cephalosporins, the color of Maxipime powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.

ADD-Vantage Instructions for Reconstitution and Intravenous Administration

To Open

Peel overwrap at corner and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

Assembly of Vial and Flexible Diluent Container

1.
Use Aseptic Technique
2.
Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:
a.
To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (See Figure 1), then pull straight up to remove the cap (See Figure 2)
b.
Once the breakaway cap has been removed, do not access vial with syringe.

                                         

 
c.
To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover (See Figure 3.)
3.
Screw the vial into the vial port until it will go no further. The Vial Must Be Screwed In Tightly To Assure a Seal. This occurs approximately 1/2 turn (180°) after the first audible click (see Figure 4). The clicking sound does not assure a seal; the vial must be turned as far as it will go. Once vial is seated, do not attempt to remove (See Figure 4).
4.
Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.
5.
Label appropriately.

                                         

Instructions for Reconstitution Maxipime ADD-Vantage Vial in Flexible Diluent Container

1.
Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.
2.
With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container (see Figure 5).
3.
Pull the inner cap from the drug vial (see Figure 6). Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.
4.
Mix container contents thoroughly and use within the specified time [see Dosage and Administration (2.6)].
5.
Look through the bottom of the vial to verify that the stopper has been removed and complete mixing has occurred (see Figure 7).
6.
If the rubber stopper is not removed from the vial and medication is not released on the first attempt, the inner cap may be manipulated back into the rubber stopper without removing the drug vial from the diluent container. Repeat steps 3 through 5.

          

Instructions for Intravenous Administration of Maxipime ADD-Vantage Vial

1.
Use Aseptic Technique
2.
Confirm the activation and admixture of vial contents.
3.
Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
4.
Close flow control clamp of administration set.
5.
Remove cover from outlet port at bottom of container.
6.
Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. Refer to full directions on administration set carton prior to use.
7.
Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
8.
Squeeze and release drip chamber to establish proper fluid level in chamber.
9.
Open flow control clamp and clear air from set. Close clamp.
10.
Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
11.
Regulate rate of administration with flow control clamp.
12.
Do not use flexible container in series connections

Dosage Forms and Strengths

Maxipime for Injection is a sterile white to pale yellow powder of cefepime in single-dose vials or ADD-Vantage vials for reconstitution and it is available in the following strengths:

0.5 gram per vial
1 g per vial
2 g per vial
1 g per ADD-Vantage vial
2 g per ADD-Vantage vial

Contraindications

Maxipime is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibiotics, penicillins or other beta-lactam antibiotics.

Warnings and Precautions

Hypersensitivity Reactions

Before therapy with Maxipime for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Maxipime occurs, discontinue the drug and institute appropriate supportive measures.

Neurotoxicity

Serious adverse reactions have been reported including life-threatening or fatal occurrences of the following: encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus [see Adverse Reactions (6.2)]. Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment. However, some cases of neurotoxicity occurred in patients receiving a dosage adjustment appropriate for their degree of renal impairment. In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis. If neurotoxicity associated with cefepime therapy occurs, discontinue cefepime and institute appropriate supportive measures.

Clostridium difficile Associated Diarrhea

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Maxipime, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Development of Drug-Resistant Bacteria

Prescribing Maxipime in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

As with other antimicrobials, prolonged use of Maxipime may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient’s condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.

Drug/Laboratory Test Interactions

Urinary Glucose

The administration of cefepime may result in a false-positive reaction for glucose in the urine when using some methods (e.g. Clinitest™ tablets) [see Drug Interactions (7.1)].

Coombs’ Tests

Positive direct Coombs’ tests have been reported during treatment with Maxipime. In patients who develop hemolytic anemia, discontinue the drug and institute appropriate therapy. Positive Coombs’ test may be observed in newborns whose mothers have received cephalosporin antibiotics before parturition.

Prothrombin Time

Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated.

Adverse Reactions

The following adverse reactions are discussed in the Warnings and Precautions section and below:

Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
Neurotoxicity [see Warnings and Precautions (5.2)]
Clostridium difficile-Associated Diarrhea [see Warnings and Precautions (5.3)]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials using multiple doses of cefepime, 4137 patients were treated with the recommended dosages of cefepime (500 mg to 2 g intravenous every 12 hours). There were no deaths or permanent disabilities thought related to drug toxicity. Sixty-four (1.5%) patients discontinued medication due to adverse reactions. Thirty-three (51%) of these 64 patients who discontinued therapy did so because of rash. The percentage of cefepime-treated patients who discontinued study drug because of drug-related adverse reactions was similar at daily doses of 500 mg, 1 g, and 2 g every 12 hours (0.8%, 1.1%, and 2%, respectively). However, the incidence of discontinuation due to rash increased with the higher recommended doses.

The following adverse reactions (Table 5) were identified in clinical trials conducted in North America (n=3125 cefepime-treated patients).

Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America

Incidence equal to or greater than 1%

Local adverse reactions (3%), including phlebitis
(1.3%), pain and/or inflammation (0.6%)*; rash
(1.1%)

Incidence less than 1% but greater than 0.1%

Colitis (including pseudomembranous colitis),
diarrhea, erythema, fever, headache, nausea,
oral moniliasis, pruritus, urticaria, vaginitis,
vomiting, anemia

At the higher dose of 2 g every 8 hours, the incidence of adverse reactions was higher among the 795 patients who received this dose of cefepime. They consisted of rash (4%), diarrhea (3%), nausea (2%), vomiting (1%), pruritus (1%), fever (1%), and headache (1%).

The following (Table 6) adverse laboratory changes, with cefepime, were seen during clinical trials conducted in North America.

Table 6: Adverse Laboratory Changes in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America
*
Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported.

Incidence equal to or greater than 1%

Positive Coombs’ test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%)

Incidence less than 1% but greater than 0.1%

Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium*, hematocrit, neutrophils, platelets, White Blood Cells (WBC)

A similar safety profile was seen in clinical trials of pediatric patients

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Maxipime. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In addition to the adverse reactions reported during the North American clinical trials with cefepime, the following adverse reactions have been reported during worldwide postmarketing experience. Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus have been reported. [see Warnings and Precautions (5.2)]

Anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia, have been reported.

Cephalosporin-Class Adverse Reactions

In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs:

Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, hepatic dysfunction including cholestasis, and pancytopenia.

Drug Interactions

Drug/Laboratory Test Interactions

The administration of cefepime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

Aminoglycosides

Monitor renal function if aminoglycosides are to be administered with Maxipime because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.

Diuretics

Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when cefepime is concomitantly administered with potent diuretics.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category B

There are no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Cefepime was not teratogenic or embryocidal when administered during the period of organogenesis to rats at doses up to 1000 mg/kg/day (1.6 times the recommended maximum human dose calculated on a body surface area basis) or to mice at doses up to 1200 mg/kg (approximately equal to the recommended maximum human dose calculated on a body surface area basis) or to rabbits at a dose level of 100 mg/kg (0.3 times the recommended maximum human dose calculated on a body surface area basis).

Labor and Delivery

Cefepime has not been studied for use during labor and delivery. Treatment should only be given if clearly indicated.

Nursing Mothers

Cefepime is excreted in human breast milk. Caution should be exercised when cefepime is administered to a nursing woman [see Clinical Pharmacology (12.3)].

Pediatric Use

The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Use of Maxipime in these age groups is supported by evidence from adequate and well-controlled studies of cefepime in adults with additional pharmacokinetic and safety data from pediatric trials [see Clinical Pharmacology (12.3)].

Safety and effectiveness in pediatric patients below the age of 2 months have not been established. There are insufficient clinical data to support the use of Maxipime in pediatric patients for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is H. influenzae type b. In those patients in whom meningeal seeding from a distant infection site or in whom meningitis is suspected or documented, an alternate agent with demonstrated clinical efficacy in this setting should be used.

Geriatric Use

Of the more than 6400 adults treated with Maxipime in clinical studies, 35% were 65 years or older while 16% were 75 years or older. When geriatric patients received the usual recommended adult dose, clinical efficacy and safety were comparable to clinical efficacy and safety in non-geriatric adult patients.

Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures [see Warnings and Precautions (5.2), Adverse Reactions (6.2)].

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored [see Clinical Pharmacology (12.3), Warnings and Precautions (5.2), Dosage and Administration (2.3)].

Renal Impairment

Adjust the dose of Maxipime in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. [See Dosage Adjustments in Patients with Renal Impairment (2.3)]

Overdosage

Patients who receive an overdose should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis, not peritoneal dialysis, is recommended to aid in the removal of cefepime from the body. Symptoms of overdose include encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures, neuromuscular excitability and nonconvulsive status epilepticus [see Warnings and Precautions (5.2), Adverse Reactions (6.2), Dosage and Administration (2.3)].

Maxipime Description

Maxipime (cefepime hydrochloride, USP) is a semi-synthetic, cephalosporin antibacterial for parenteral administration. The chemical name is 1 - [[(6R,7R) - 7 - [2 - (2 - amino - 4 - thiazolyl) - glyoxylamido] - 2 - carboxy - 8 - oxo - 5 - thia - 1 - azabicyclo[4.2.0] oct - 2 - en - 3 - yl]methyl] - 1 - methylpyrrolidinium chloride,72-(Z)-(O-methyloxime), monohydrochloride, monohydrate, which corresponds to the following structural formula:

Cefepime hydrochloride is a white to pale yellow powder. Cefepime hydrochloride contains the equivalent of not less than 825 mcg and not more than 911 mcg of cefepime (C19H24N6O5S2) per mg, calculated on an anhydrous basis. It is highly soluble in water.

Maxipime for Injection is supplied for intramuscular or intravenous administration in strengths equivalent to 500 mg, 1 g, and 2 g of cefepime. Maxipime is a sterile, dry mixture of cefepime hydrochloride and L-arginine. The L-arginine, at an approximate concentration of 707 mg/g of cefepime, is added to control the pH of the constituted solution at 4 to 6. Freshly constituted solutions of Maxipime will range in color from pale yellow to amber.

Maxipime - Clinical Pharmacology

Mechanism of Action

Cefepime is a cephalosporin antibacterial drug [See Microbiology (12.4)].

Pharmacodynamics

Similar to other beta-lactam antimicrobial agents, the time that the unbound plasma concentration of cefepime exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in animal models of infection. However, the pharmacokinetic/pharmacodynamics relationship for cefepime has not been evaluated in patients.

Pharmacokinetics

Pharmacokinetic parameters for cefepime in healthy adult male volunteers (n=9) following single
30-minute infusions (IV) of cefepime 500 mg, 1 g, and 2 g are summarized in Table 7. Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers. Cefepime pharmacokinetics are linear over the range 250 mg to 2 g. There is no evidence of accumulation in healthy adult male volunteers (n=7) receiving clinically relevant doses for a period of 9 days.

Table 7: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intravenous Administration

Maxipime

Parameter

500 mg IV

1 g IV

2 g IV

Cmax, mcg/mL

39.1 (3.5)

81.7 (5.1)

163.9 (25.3)

AUC, h•mcg/mL

70.8 (6.7)

148.5 (15.1)

284.8 (30.6)

Number of subjects

9

9

9

(male)

Pharmacokinetic parameters for cefepime following a single intramuscular injection are summarized in Table 8. The pharmacokinetics of cefepime are linear over the range of 500 mg to 2 g intramuscularly and do not vary with respect to treatment duration.

Table 8: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intramuscular Administration

Maxipime

Parameter

500 mg IM

1 g IM

2 g IM

Cmax, mcg/mL

13.9 (3.4)

29.6 (4.4)

57.5 (9.5)

Tmax, h

1.4 (0.9)

1.6 (0.4)

1.5 (0.4)

AUC, h•mcg/mL

60 (8)

137 (11)

262 (23)

Number of subjects

6

6

12

(male)

Absorption

Following intramuscular (IM) administration, cefepime is completely absorbed.

Distribution

The average steady-state volume of distribution of cefepime is 18 (±2) L. The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum.

Cefepime is excreted in human milk at a concentration of 0.5 mcg/mL. A nursing infant consuming approximately 1000 mL of human milk per day would receive approximately 0.5 mg of cefepime per day [see Use in Specific Populations (8.3)].

Concentrations of cefepime achieved in specific tissues and body fluids are listed in Table 9.

Table 9: Mean Concentrations of Cefepime in Specific Body Fluids (mcg/mL) or Tissues (mcg/g)

Tissue or Fluid

Dose/Route

# of Patients

Mean Time of Sample Post-Dose

(h)

Mean Concentration

Blister Fluid

2 g IV

6

1.5

81.4 mcg/mL

Bronchial Mucosa

2 g IV

20

4.8

24.1 mcg/g

Sputum

2 g IV

5

4

7.4 mcg/mL

Urine

500 mg IV

8

0 to 4

292 mcg/mL

1 g IV

12

0 to 4

926 mcg/mL

2 g IV

12

0 to 4

3120 mcg/mL

Bile

2 g IV

26

9.4

17.8 mcg/mL

Peritoneal Fluid

2 g IV

19

4.4

18.3 mcg/mL

Appendix

2 g IV

31

5.7

5.2 mcg/g

Gallbladder

2 g IV

38

8.9

11.9 mcg/g

Prostate

2 g IV

5

1

31.5 mcg/g

Data suggest that cefepime does cross the inflamed blood-brain barrier. The clinical relevance of these data is uncertain at this time.

Metabolism and Excretion

Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime. Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment [see Dosage and Administration (2.3)].

Specific Populations

Patients with Renal impairment

Cefepime pharmacokinetics have been investigated in patients with various degrees of renal impairment (n=30). The average half-life in patients requiring hemodialysis was 13.5 (±2.7) hours and in patients requiring continuous peritoneal dialysis was 19 (±2) hours. Cefepime total body clearance decreased proportionally with creatinine clearance in patients with abnormal renal function, which serves as the basis for dosage adjustment recommendations in this group of patients [see Dosage and Administration (2.3)].

Patients with Hepatic impairment

The pharmacokinetics of cefepime were unaltered in patients with hepatic impairment who received a single 1 g dose (n=11).

Geriatric patients

Cefepime pharmacokinetics have been investigated in elderly (65 years of age and older) men (n=12) and women (n=12) whose mean (SD) creatinine clearance was 74 (±15) mL/min. There appeared to be a decrease in cefepime total body clearance as a function of creatinine clearance. Therefore, dosage administration of cefepime in the elderly should be adjusted as appropriate if the patient’s creatinine clearance is 60 mL/min or less [see Dosage and Administration (2.3)].

Pediatric patients

Cefepime pharmacokinetics have been evaluated in pediatric patients from 2 months to 11 years of age following single and multiple doses on every 8 hours (n=29) and every 12 hours (n=13) schedules. Following a single intravenous dose, total body clearance and the steady-state volume of distribution averaged 3.3 (±1) mL/min/kg and 0.3 (±0.1) L/kg, respectively. The urinary recovery of unchanged cefepime was 60.4 (±30.4)% of the administered dose, and the average renal clearance was 2 (±1.1) mL/min/kg. There were no significant effects of age or gender (25 male vs. 17 female) on total body clearance or volume of distribution, corrected for body weight. No accumulation was seen when cefepime was given at 50 mg per kg every 12 hours (n=13), while Cmax, AUC, and t½ were increased about 15% at steady state after 50 mg per kg every 8 hours. The exposure to cefepime following a 50 mg per kg intravenous dose in a pediatric patient is comparable to that in an adult treated with a 2 g intravenous dose. The absolute bioavailability of cefepime after an intramuscular dose of 50 mg per kg was 82.3 (±15)% in eight patients.

Microbiology

Mechanism of Action

Cefepime is a bactericidal drug that acts by inhibition of bacterial cell wall synthesis. Cefepime has a broad spectrum of in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP).

Antimicrobial Activity

Cefepime has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the Indications and Usage section (1).

Gram-negative Bacteria
Enterobacter spp.
Escherichia coli
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa

Gram-positive Bacteria
Staphylococcus aureus (methicillin-susceptible isolates only)
Streptococcus pneumoniae
Streptococcus pyogenes
Viridans group streptococci

The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefepime against isolates of similar genus or organism group. However, the efficacy of cefepime in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials.

Gram-positive Bacteria
Staphylococcus epidermidis (methicillin-susceptible isolates only)
Staphylococcus saprophyticus
Streptococcus agalactiae

NOTE: Most isolates of enterococci, e.g., Enterococcus faecalis, and methicillin-resistant staphylococci are resistant to cefepime.

Gram-negative Bacteria
Acinetobacter calcoaceticus subsp. lwoffii
Citrobacter diversus
Citrobacter freundii
Enterobacter agglomerans
Haemophilus influenzae
Hafnia alvei
Klebsiella oxytoca
Moraxella catarrhalis
Morganella morganii
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Serratia marcescens

NOTE: Cefepime is inactive against many isolates of Stenotrophomonas maltophilia.

Susceptibility Test Methods

When available, the clinical microbiology laboratory should provide cumulative reports of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.

Dilution techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method 1,2 (broth and/or agar). The MIC should be interpreted according to criteria provided in Table 10.

Diffusion techniques

Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method 2,3. This procedure uses paper discs impregnated with 30 mcg cefepime to test the susceptibility of microorganisms to cefepime. The disk diffusion interpretive criteria are provided in Table 10.

Table 10: Susceptibility Test Interpretive Criteria for Cefepime¥
¥For patients with renal impairment see Table 2 in Dosage and Administration.
*For isolates of Enterobacteriaceae with intermediate susceptibility, use a dose of 2 g every 8 hours in patients with normal renal function.
§For P. aeruginosa, use 2 g IV every 8 hours in patients with normal renal function
bFor non-meningitis isolates, a penicillin MIC of < 0.06 mcg/ml (or oxacillin zone > 20 mm) can predict susceptibility to cefepime.

Pathogen

Minimum Inhibitory
Concentrations
(mcg/ml)

Disk Diffusion Zone Diameters
(mm)

(S)
Susceptible

(I)
Intermediate

(R)
Resistant

(S)
Susceptible

(I)
Intermediate

(R)
Resistant

Enterobacteriaceae

≤2

4 to 8*

≥16

≥25

19 to 24*

≤18

Pseudomonas
aeruginosa§

≤8

-

≥16

≥18

-

≤17

Streptococcus

pneumoniaeb

non-meningitis
isolates

≤1

2

≥4

-

-

-

Streptococcus
pyogenes

≤0.5

-

-

≥24

-

-

Viridans group streptococci

≤1

2

≥4

≥24

22 to 23

≤21

Susceptibility of staphylococci to cefepime may be deduced from testing only penicillin and either cefoxitin or oxacillin.

A report of Susceptible (S) indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test 1,2,3. Standard cefepime powder should provide the following range of MIC values noted in Table 11. For the diffusion technique using the 30 mcg disc, the criteria in Table 11 should be achieved.

Table 11: Acceptable Quality Control Ranges for Cefepime

QC Strain

Minimum Inhibitory
Concentrations (mcg/mL)

Disk Diffusion (zone
diameters in mm)

Escherichia coli ATCC 25922

0.015 to 0.12

31 to 37

Staphylococcus aureus
ATCC 29213

1 to 4

-

Staphylococcus aureus
ATCC 25923

-

23 to 29

Pseudomonas aeruginosa
ATCC 27853

0.5 to 4

24 to 30

Streptococcus pneumoniae
ATCC 49619

0.03 to 0.25

28 to 35

Haemophilus influenzae
ATCC 49247

0.5 to 2

25 to 31

Neisseria gonorrhoeae
ATCC 49226

0.015 to 0.06

37 to 46

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal carcinogenicity studies have been conducted with cefepime. In chromosomal aberration studies, cefepime was positive for clastogenicity in primary human lymphocytes, but negative in Chinese hamster ovary cells. In other in vitro assays (bacterial and mammalian cell mutation, DNA repair in primary rat hepatocytes, and sister chromatid exchange in human lymphocytes), cefepime was negative for genotoxic effects. Moreover, in vivo assessments of cefepime in mice (2 chromosomal aberration and 2 micronucleus studies) were negative for clastogenicity. No untoward effects on fertility were observed in rats when cefepime was administered subcutaneously at doses up to 1000 mg/kg/day (1.6 times the recommended maximum human dose calculated on a body surface area basis).

Clinical Studies

Febrile Neutropenic Patients

The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients. Table 12 describes the characteristics of the evaluable patient population.

Table 12: Demographics of Evaluable Patients (First Episodes Only)
ANC = absolute neutrophil count; SBP = systolic blood pressure

Cefepime

Ceftazidime

Total

164

153

Median age (yr)

56 (range, 18 to 82)

55 (range, 16 to 84)

Male

86 (52%)

85 (56%)

Female

78 (48%)

68 (44%)

Leukemia

65 (40%)

52 (34%)

Other hematologic malignancies

43 (26%)

36 (24%)

Solid tumor

54 (33%)

56 (37%)

Median ANC nadir (cells/microliter)

20 (range, 0 to 500)

20 (range, 0 to 500)

Median duration of neutropenia (days)

6 (range, 0 to 39)

6 (range, 0 to 32)

Indwelling venous catheter

97 (59%)

86 (56%)

Prophylactic antibiotics

62 (38%)

64 (42%)

Bone marrow graft

9 (5%)

7 (5%)

SBP less than 90 mm Hg at entry

7 (4%)

2 (1%)

Table 13 describes the clinical response rates observed. For all outcome measures, cefepime was therapeutically equivalent to ceftazidime.

Table 13: Pooled Response Rates for Empiric Therapy of Febrile Neutropenic Patients

% Response

Cefepime

Ceftazidime

Outcome Measures

(n=164)

(n=153)

Primary episode resolved with no treatment modification, no
new febrile episodes or infection, and oral antibiotics allowed
for completion of treatment

51

55

Primary episode resolved with no treatment modification, no
new febrile episodes or infection and no post-treatment oral
antibiotics

34

39

Survival, any treatment modification allowed

93

97

Primary episode resolved with no treatment modification and
oral antibiotics allowed for completion of treatment

62

67

Primary episode resolved with no treatment modification and no
post-treatment oral antibiotics

46

51

Insufficient data exist to support the efficacy of cefepime monotherapy in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia). No data are available in patients with septic shock.

Complicated Intra-abdominal Infections

Patients hospitalized with complicated intra-abdominal infections participated in a randomized, double-blind, multicenter trial comparing the combination of cefepime (2 g every 12 hours) plus intravenous metronidazole (500 mg every 6 hours) versus imipenem/cilastatin (500 mg every 6 hours) for a maximum duration of 14 days of therapy. The study was designed to demonstrate equivalence of the two therapies. The primary analyses were conducted on the population consisting of those with a surgically confirmed complicated infection, at least one pathogen isolated pretreatment, at least 5 days of treatment, and a 4 to 6 week follow-up assessment for cured patients. Subjects in the imipenem/cilastatin arm had higher APACHE II scores at baseline. The treatment groups were otherwise generally comparable with regard to their pretreatment characteristics. The overall clinical cure rate among the primary analysis patients was 81% (51 cured/63 evaluable patients) in the cefepime plus metronidazole group and 66% (62/94) in the imipenem/cilastatin group. The observed differences in efficacy may have been due to a greater proportion of patients with high APACHE II scores in the imipenem/cilastatin group.

REFERENCES

1.
Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Tenth Edition. CLSI document M07-10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
2.
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-sixth Informational Supplement, CLSI document M100-S26. CLSI document M100-S26, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2016.
3.
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition. CLSI document M02-A12, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
4.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.

How Supplied/Storage and Handling

How Supplied

Maxipime for injection is supplied as follows: Maxipime for Injection in the dry state, is a white to pale yellow powder. Constituted solution of Maxipime can range in color from pale yellow to amber.

*
Based on cefepime activity.

Unit of Sale

Strength

Each

NDC 0409-0221-01

Carton containing 10

500 mg*

NDC 0409-0221-11

Vial

NDC 0409-0219-01

Carton containing 10

1 gram*

NDC 0409-0219-11

Vial

NDC 0409-0220-01

Carton containing 10

2 grams*

NDC 0409-0220-11

Vial

NDC 0409-0217-01

Carton containing 25

1 gram*

NDC 0409-0217-11

ADD-VantageTM Vial

NDC 0409-0218-01

Carton containing 25

2 grams*

NDC 0409-0218-11

ADD-VantageTM Vial

Storage and Handling

Maxipime for injection in the dry state should be stored at 20 to 25° C (68 to 77° F) [see USP controlled room temperature.] and protected from light.

Patient Counseling Information

Counsel patients that antibacterial drugs including Maxipime should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Maxipime is prescribed to treat a bacterial infection, tell patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Maxipime or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibacterial drugs, which usually ends when the antibiotic is discontinued. Inform patient that they may develop watery and bloody stools (with or without stomach cramps and fever) during treatment and as late as two or more months after having taken the last dose of the antibiotic. Inform patients that they should contact their physician as soon as possible if this occurs.
Advise patients of neurological adverse events that could occur with Maxipime use. Instruct patients or their caregivers to inform their healthcare provider at once of any neurological signs and symptoms, including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia (disturbance of speaking and understanding spoken and written language), myoclonus, seizures and nonconvulsive status epilepticus, for immediate treatment, dosage adjustment, or discontinuation of Maxipime.

Manufactured for: Hospira, Inc.                                                                                                    
Lake Forest, IL 60045 USA

Made in India

EN-4225

948026410

CA-3713

CA-3714

CA-3711

CA-3712

CA-3710

Maxipime 
cefepime injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-0217
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CEFEPIME HYDROCHLORIDE (CEFEPIME) CEFEPIME 1 g
Inactive Ingredients
Ingredient Name Strength
ARGININE  
Packaging
# Item Code Package Description
1 NDC:0409-0217-01 25 VIAL, PATENT DELIVERY SYSTEM in 1 CARTON
1 NDC:0409-0217-11 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050679 01/18/1996
Maxipime 
cefepime injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-0218
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CEFEPIME HYDROCHLORIDE (CEFEPIME) CEFEPIME 2 g
Inactive Ingredients
Ingredient Name Strength
ARGININE  
Packaging
# Item Code Package Description
1 NDC:0409-0218-01 25 VIAL, PATENT DELIVERY SYSTEM in 1 CARTON
1 NDC:0409-0218-11 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050679 01/18/1996
Maxipime 
cefepime injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-0219
Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CEFEPIME HYDROCHLORIDE (CEFEPIME) CEFEPIME 1 g
Inactive Ingredients
Ingredient Name Strength
ARGININE  
Packaging
# Item Code Package Description
1 NDC:0409-0219-01 10 VIAL, SINGLE-DOSE in 1 CARTON
1 NDC:0409-0219-11 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050679 01/18/1996
Maxipime 
cefepime injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-0220
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CEFEPIME HYDROCHLORIDE (CEFEPIME) CEFEPIME 2 g
Inactive Ingredients
Ingredient Name Strength
ARGININE  
Packaging
# Item Code Package Description
1 NDC:0409-0220-01 10 VIAL, SINGLE-DOSE in 1 CARTON
1 NDC:0409-0220-11 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050679 01/18/1996
Maxipime 
cefepime injection, powder, for solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0409-0221
Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CEFEPIME HYDROCHLORIDE (CEFEPIME) CEFEPIME 500 mg
Inactive Ingredients
Ingredient Name Strength
ARGININE  
Packaging
# Item Code Package Description
1 NDC:0409-0221-01 10 VIAL, SINGLE-DOSE in 1 CARTON
1 NDC:0409-0221-11 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050679 01/18/1996
Labeler - Hospira, Inc. (141588017)
Revised: 03/2016
 
Hospira, Inc.
Hide